Sarah Volinsky-Fremond

Sarah Volinsky-Fremond

Auto-generated profile, based on publicly available information

Sarah Volinsky-Fremond

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
NHNanda Horeweg
Nanda Horeweg
SASonali Andani
Sonali Andani
JWJurriaan Barkey Wolf
Jurriaan Barkey Wolf
MLMaxime W. Lafarge
Maxime W. Lafarge
TBTjalling Bosse
Tjalling Bosse
Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. Here we developed HECTOR (histopathology-based endometrial cancer tailored outcome risk), a multimodal deep learning prognostic model using hematoxylin and eosin-stained, whole-slide images and tumor stage as input, on 2,072 patients from eight EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal (n = 353) and two external (n = 160 andn = 151) test sets of 0.789, 0.828 and 0.815, respectively, outperforming the current gold standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low-, intermediate- and high-risk groups, respectively, by Kaplan–Meier analysis). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold standard and may help delivery of personalized treatment in EC.

1 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
NHNanda Horeweg
Nanda Horeweg
SASonali Andani
Sonali Andani
JWJurriaan Barkey Wolf
Jurriaan Barkey Wolf
MLMaxime W. Lafarge
Maxime W. Lafarge
TBTjalling Bosse
Tjalling Bosse

9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NBNikki van Den Berg
Nikki van Den Berg
LSLydia Schoenpflug
Lydia Schoenpflug
NHNanda Horeweg
Nanda Horeweg
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
JBJurriaan Barkey-Wolf
Jurriaan Barkey-Wolf
TBTjalling Bosse
Tjalling Bosse
POLE sequencing for somatic mutations ( POLE mut) guides adjuvant therapy in endometrial cancer (EC), but cost and infrastructural considerations lead to limited uptake. Omission of POLE testing leads to unnecessary exposure to radiotherapy and/or chemotherapy. We developed POLARIX, a multiple instance deep learning model with attention pooling, which predicts POLE mutation status from routine hematoxylin and eosin whole-slide images (WSIs). Trained on 2,238 cases from eleven EC cohorts, POLARIX showed clinical-grade discrimination across three external cohorts (Pooled: AUC=0.95, 95% CI: 0.91–0.98; n =68/481 POLE mut/ POLE wt). Attention maps highlight POLE morphologies. Clinical applicability is demonstrated using predefined thresholds based on three resource scenarios. The most sensitive threshold (“Low”) yields a test reduction of 77% (73%-81%) (sensitivity: 93% (85%-99%), specificity: 89% (87%-92%)). POLARIX is an interpretable and cost-efficient approach to reduce POLE testing in women with endometrial cancer, broadening access to precision oncology.

27 November 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SFSarah Fremond-Volinsky
Sarah Fremond-Volinsky
NHNanda Horeweg
Nanda Horeweg
SASonali Andani
Sonali Andani
JWJurriaan Barkey Wolf
Jurriaan Barkey Wolf
MLMaxime W Lafarge
Maxime W Lafarge
TBTjalling Bosse
Tjalling Bosse
Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. We developed HECTOR ( H istopathology-based E ndometrial C ancer T ailored O utcome R isk), a multimodal deep learning prognostic model using hematoxylin-and-eosin-stained whole-slide-images and tumor stage as input, on 1,912 patients from seven EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal ( n = 353) and external ( n = 151) test sets of 0.788 and 0.816 respectively, outperforming the current gold-standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low, intermediate and high risk groups). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold-standard and may help delivery of personalized treatment in EC.

25 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
NBNikki van Den Berg
Nikki van Den Berg
JWJurriaan Barkey Wolf
Jurriaan Barkey Wolf
LSLydia A. Schoenpflug
Lydia A. Schoenpflug
SASonali Andani
Sonali Andani
NHNanda Horeweg
Nanda Horeweg
Computational pathology leverages deep learning to extract clinically relevant information from digitized tumor slides, predicting histopathological subtypes, molecular alterations, and patient outcomes. Recent pipelines increasingly rely on foundation models trained on large pan-cancer datasets to generate generalizable features. In endometrial cancer (EC), their comparative performance for clinical diagnostic tasks remains unexplored. For the first time, this study evaluates the performance of seven state-of-the-art foundation models across morphological, molecular, and prognostic tasks using a large EC dataset of 3,293 patients from randomized trials and clinical cohorts. In addition, their performance was compared to one model (EsVIT) exclusively trained on EC. The foundation models H-OPTIMUS-0, CONCH, and VIRCHOW2, achieved the highest mean performance, but the best-performing foundation model varied by task. The top-performing foundation model outperformed the EC-specific feature extractor EsVIT across all tasks. This study highlights the superiority of foundation models over a domain-specific feature extractor in EC. Selecting the optimal foundation model for novel tasks remains challenging due to performance plateaus and limited information on the training datasets, requiring rigorous benchmarking and domain insight to reach maximum potential.